Tiziana To Treat Multiple Sclerosis Patient With Nasal Administration of Foralumab

The FDA has allowed evaluation of Tiziana Life Sciences Plc's TLSA nasal administration with foralumab in a secondary progressive multiple sclerosis (SPMS) patient at the Brigham and Women's Hospital (BWH), Harvard University.

  • The patient will be treated under an Individual Patient Expanded Access IND.
  • The treatment is planned to start in the second quarter of this year and will continue for six months.
  • Investigators will follow this patient with detailed routine safety, neurological imaging, and PET studies to evaluate microglial imaging.
  • Previously, Tiziana completed a Phase 1 trial of multiple ascending doses once a day, dosing for five consecutive days with nasally administered Foralumab in healthy subjects.
  • The treatment was well-tolerated with no drug-related safety issues reported at any dose up to 250 mg of the quantities.
  • Earlier today, the company announced a controlled Phase 2 trial in Brazil for foralumab in moderate to severe hospitalized COVID-19 patients.
  • Price Action: TLSA shares are trading 7.9% higher at $2.86 in market hours on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFDAGeneralmultiple sclerosis
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!